FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1488331458> ?p ?o ?g. }

• W1488331458 abstract "A long time and many steps are needed to bring valuable drugs to patients. Drugs not only have to be effective against the disease which they are intended for, but also safe. All drugs cause toxic effects in proportion to the dose (Paracelsus, ca. XVI cent.). Therefore, assessing carefully the optimal dose at the desired benefit/risk ratio (Stevens and Baker, 2009) and characterizing mechanisms of toxicity are essential for maintaining high safety standards. The experimental strategies used to predict drugs’ adverse events are many, and include the use of non-invasive biomarkers that can ideally be translated from test species to humans. In particular, cardiac safety requires special attentions, as it causes the cessation of drug development in over the 30% of cases due to toxic liabilities in Phase III, and over 40% post-approval (Redfern et al., 2011).In 1993 Victor Ambros, Rosalind Lee and Rhonda Feinbaum (Lee et al., 1993) described for the first time in C. elegans the role of short non-coding RNAs, called microRNAs. MicroRNAs pair with target mRNAs via sequence complementarity, and lead to mRNA degradation or translation inhibition (Filipowicz et al., 2008; Guo et al., 2010). MicroRNAs are implicated in many biological processes and in the evolution of the complexity of superior organisms, for review see (Bartel, 2004; Berezikov, 2011). Their role in cardiovascular development and diseases has been supported by an increasing number of publications, for review see (Kinet et al., 2012; Small and Olson, 2011). Recently, tissue-specific microRNAs were found in a variety of body fluids following drug-induced tissue injury (Wang et al., 2009). In particular, myocardial necrosis of different etiologies (such as acute coronary syndrome and myocardial infarction) caused an increase of heart enriched microRNAs in plasma/serum of patients, as reviewed by (McManus and Ambros, 2011). This work is aimed at increasing our knowledge about cardiac microRNAs function in different toxicological contexts and across species.Chapter 1 will give an overview of drug safety assessment focusing on the cardiovascular system, microRNAs biology and their potential as toxicity biomarkers.In Chapter 2 I will illustrate an example of drug-induced cardiac injury, and its impact on expression of microRNAs in rats’ hearts. Chronic treatment of rats with low amounts of doxorubicin (an anti-tumoral compound) caused myocardial vacuolation in ventricular tissue and a significant increase of specific microRNAs and genomic indicators of cardiomyopathy. We found that Sipa1 could be directly inhibited by miR-34c by using a luciferase assay. Notably, the phenotypic anchoring of microRNAs with histopathological read-outs in the tissue showed that over-expression of miR-216b in the heart preceded the rise of overt lesions.Chapter 3 will describe an approach to determine the distribution of mRNAs and microRNAs in different cardiac structures in rat, dog and Cynomolgus monkey. We showed that microRNAs could discriminate the different heart structures as good as mRNAs. We also assessed the expected anti-correlation between microRNAs levels and their predicted target mRNAs, and showed that mRNAs of 4 genes implicated in cardiac diseases and muscular development could be inhibited at the post-transcriptional level by 4 distinct microRNAs. We propose that our mRNAs and microRNAs data sets could be used to assess the human relevance of preclinical findings in these 3 species, and to derive potential tissue and circulating biomarkers for drug-induced cardiac injury.In conclusion, profiling microRNAs have the potential to help biomedical research in bringing drugs to patients, since they can shed light on toxicity mechanisms in the tissues (Taylor and Gant, 2008) and are a source of translatable non-invasive toxicity biomarkers in body fluids." @default.
• W1488331458 created "2016-06-24" @default.
• W1488331458 creator A5053712202 @default.
• W1488331458 date "2012-01-01" @default.
• W1488331458 modified "2023-09-23" @default.
• W1488331458 title "MicroRNAs regulatory networks in cardiotoxicity" @default.
• W1488331458 doi "https://doi.org/10.5451/unibas-005977132" @default.
• W1488331458 hasPublicationYear "2012" @default.
• W1488331458 type Work @default.
• W1488331458 sameAs 1488331458 @default.
• W1488331458 citedByCount "0" @default.
• W1488331458 crossrefType "dissertation" @default.
• W1488331458 hasAuthorship W1488331458A5053712202 @default.
• W1488331458 hasConcept C104317684 @default.
• W1488331458 hasConcept C126322002 @default.
• W1488331458 hasConcept C145059251 @default.
• W1488331458 hasConcept C197934379 @default.
• W1488331458 hasConcept C2778233292 @default.
• W1488331458 hasConcept C29730261 @default.
• W1488331458 hasConcept C33070731 @default.
• W1488331458 hasConcept C54355233 @default.
• W1488331458 hasConcept C60644358 @default.
• W1488331458 hasConcept C70721500 @default.
• W1488331458 hasConcept C71924100 @default.
• W1488331458 hasConcept C86803240 @default.
• W1488331458 hasConcept C98274493 @default.
• W1488331458 hasConceptScore W1488331458C104317684 @default.
• W1488331458 hasConceptScore W1488331458C126322002 @default.
• W1488331458 hasConceptScore W1488331458C145059251 @default.
• W1488331458 hasConceptScore W1488331458C197934379 @default.
• W1488331458 hasConceptScore W1488331458C2778233292 @default.
• W1488331458 hasConceptScore W1488331458C29730261 @default.
• W1488331458 hasConceptScore W1488331458C33070731 @default.
• W1488331458 hasConceptScore W1488331458C54355233 @default.
• W1488331458 hasConceptScore W1488331458C60644358 @default.
• W1488331458 hasConceptScore W1488331458C70721500 @default.
• W1488331458 hasConceptScore W1488331458C71924100 @default.
• W1488331458 hasConceptScore W1488331458C86803240 @default.
• W1488331458 hasConceptScore W1488331458C98274493 @default.
• W1488331458 hasLocation W14883314581 @default.
• W1488331458 hasOpenAccess W1488331458 @default.
• W1488331458 hasPrimaryLocation W14883314581 @default.
• W1488331458 hasRelatedWork W1972408423 @default.
• W1488331458 hasRelatedWork W1974659767 @default.
• W1488331458 hasRelatedWork W2003306436 @default.
• W1488331458 hasRelatedWork W2028986672 @default.
• W1488331458 hasRelatedWork W2061550402 @default.
• W1488331458 hasRelatedWork W2076214847 @default.
• W1488331458 hasRelatedWork W2109617340 @default.
• W1488331458 hasRelatedWork W2147904877 @default.
• W1488331458 hasRelatedWork W2187244644 @default.
• W1488331458 hasRelatedWork W2272403709 @default.
• W1488331458 hasRelatedWork W2335041549 @default.
• W1488331458 hasRelatedWork W2387243664 @default.
• W1488331458 hasRelatedWork W2418260419 @default.
• W1488331458 hasRelatedWork W2779090646 @default.
• W1488331458 hasRelatedWork W2785385438 @default.
• W1488331458 hasRelatedWork W2918564295 @default.
• W1488331458 hasRelatedWork W2971557368 @default.
• W1488331458 hasRelatedWork W2998515599 @default.
• W1488331458 hasRelatedWork W3120487598 @default.
• W1488331458 hasRelatedWork W3210172703 @default.
• W1488331458 isParatext "false" @default.
• W1488331458 isRetracted "false" @default.
• W1488331458 magId "1488331458" @default.
• W1488331458 workType "dissertation" @default.